Delta-Fly Pharma, Inc. (4598.T)

JPY 714.0

(3.18%)

Market Cap (In JPY)

6.43 Billion

Revenue (In JPY)

-

Net Income (In JPY)

-1.42 Billion

Avg. Volume

155.08 Thousand

Currency
JPY
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
445.0-1078.0
PE
-
EPS
-
Beta Value
0.057
ISIN
JP3549370009
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Kiyoshi Eshima
Employee Count
-
Website
https://www.delta-flypharma.co.jp
Ipo Date
2018-10-12
Details
Delta-Fly Pharma, Inc. develops anticancer drugs. It develops DFP-10917 that is in phase III clinical trial in the United States and phase I trial in Japan for the treatment of relapsed/refractory acute myeloid leukemia; DFP-14323, which is in phase III clinical trial to treat lung cancer; DFP-17729 that is in phase I/II clinical trials for the treatment of solid cancer; DFP-11207, which has completed phase I clinical trial to treat pancreatic cancer; DFP-14927 that is in phase I for the treatment of hematologic cancer; and DFP-10825, which is in preclinical trial to treat gastric/ovarian cancer. Delta-Fly Pharma, Inc. was incorporated in 2010 and is headquartered in Tokushima, Japan.